1649 related articles for article (PubMed ID: 34739043)
1. Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years.
Eliakim-Raz N; Leibovici-Weisman Y; Stemmer A; Ness A; Awwad M; Ghantous N; Stemmer SM
JAMA; 2021 Dec; 326(21):2203-2204. PubMed ID: 34739043
[TBL] [Abstract][Full Text] [Related]
2. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L
Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
4. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer.
Massarweh A; Eliakim-Raz N; Stemmer A; Levy-Barda A; Yust-Katz S; Zer A; Benouaich-Amiel A; Ben-Zvi H; Moskovits N; Brenner B; Bishara J; Yahav D; Tadmor B; Zaks T; Stemmer SM
JAMA Oncol; 2021 Aug; 7(8):1133-1140. PubMed ID: 34047765
[TBL] [Abstract][Full Text] [Related]
5. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
Gilboa M; Mandelboim M; Indenbaum V; Lustig Y; Cohen C; Rahav G; Asraf K; Amit S; Jaber H; Nemet I; Kliker L; Bar-Haim E; Mendelson E; Doolman R; Rubin C; Regev-Yochay G; Kreiss Y
J Infect Dis; 2022 Mar; 225(5):785-792. PubMed ID: 34850049
[TBL] [Abstract][Full Text] [Related]
6. Association of Vaccine Type and Prior SARS-CoV-2 Infection With Symptoms and Antibody Measurements Following Vaccination Among Health Care Workers.
Debes AK; Xiao S; Colantuoni E; Egbert ER; Caturegli P; Gadala A; Milstone AM
JAMA Intern Med; 2021 Dec; 181(12):1660-1662. PubMed ID: 34398173
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
8. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
Manisty C; Otter AD; Treibel TA; McKnight Á; Altmann DM; Brooks T; Noursadeghi M; Boyton RJ; Semper A; Moon JC
Lancet; 2021 Mar; 397(10279):1057-1058. PubMed ID: 33640038
[No Abstract] [Full Text] [Related]
9. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.
Shroff RT; Chalasani P; Wei R; Pennington D; Quirk G; Schoenle MV; Peyton KL; Uhrlaub JL; Ripperger TJ; Jergović M; Dalgai S; Wolf A; Whitmer R; Hammad H; Carrier A; Scott AJ; Nikolich-Žugich J; Worobey M; Sprissler R; Dake M; LaFleur BJ; Bhattacharya D
Nat Med; 2021 Nov; 27(11):2002-2011. PubMed ID: 34594036
[TBL] [Abstract][Full Text] [Related]
10. Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination.
Ali H; Alterki A; Sindhu S; Alahmad B; Hammad M; Al-Sabah S; Alghounaim M; Jamal MH; Aldei A; Mairza MJ; Husain M; Deverajan S; Ahmad R; Cherian P; Alkhairi I; Alkandari A; Abubaker J; Abu-Farha M; Al-Mulla F
Front Immunol; 2021; 12():752233. PubMed ID: 34899701
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
[No Abstract] [Full Text] [Related]
12. A network analysis of COVID-19 mRNA vaccine patents.
Gaviria M; Kilic B
Nat Biotechnol; 2021 May; 39(5):546-548. PubMed ID: 33981074
[No Abstract] [Full Text] [Related]
13. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
14. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
Huang Q; Ji K; Tian S; Wang F; Huang B; Tong Z; Tan S; Hao J; Wang Q; Tan W; Gao GF; Yan J
Nat Commun; 2021 Feb; 12(1):776. PubMed ID: 33536425
[TBL] [Abstract][Full Text] [Related]
15. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
16. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing SARS-CoV-2.
Poeschla E
Elife; 2020 Dec; 9():. PubMed ID: 33320086
[TBL] [Abstract][Full Text] [Related]
18. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
19. Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine.
Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
Fukushima J Med Sci; 2022 Apr; 68(1):67-70. PubMed ID: 35228456
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 anti-spike IgG antibodies are present in all liver transplant recipients after fifth vaccine dose.
Smeets JJH; van Malenstein H; van der Merwe S; Nevens F; Verbeek J
J Hepatol; 2024 Jun; 80(6):e284-e286. PubMed ID: 38110008
[No Abstract] [Full Text] [Related]
[Next] [New Search]
